Table 2.
Medication Use by Region and Overall
| US (N = 25) | Europea (N = 50) | Brazil (N = 10) | Total (N = 85) | |
|---|---|---|---|---|
| Current PsA medication typeb | ||||
| DMARD type, n (%) | ||||
| Any DMARD | 25 (100.0) | 50 (100.0) | 10 (100.0) | 85 (100.0) |
| csDMARD monotherapy (no bDMARD) | 5 (20.0) | 25 (50.0) | 5 (50.0) | 35 (41.2) |
| MTX (included in csDMARD monotherapy) | 5 (100.0) | 19 (76.0) | 2 (40.0) | 26 (74.3) |
| bDMARD monotherapy (no csDMARD) | 9 (36.0) | 15 (30.0) | 4 (40.0) | 28 (32.9) |
| csDMARD + bDMARD (combination therapy) | 9 (36.0) | 10 (20.0) | 1 (10.0) | 20 (23.5) |
| MTX (included in csDMARD + bDMARD) | 7 (77.8) | 8 (80.0) | 1 (100.0) | 16 (80.0) |
| tsDMARD (apremilast) | 2 (8.0) | 0 (0) | 0 (0) | 2 (2.4) |
| Steroid, n (%) | 0 (0) | 10 (20.0) | 0 (0) | 10 (11.8) |
| csDMARDs,c n (%) | 16 (64.0) | 35 (70.0) | 6 (60.0) | 57 (67.1) |
| MTX | 12 (75.0) | 27 (77.1) | 3 (50.0) | 42 (73.7) |
| Oral | 9 (75.0) | 17 (63.0) | 3 (100.0) | 29 (69.0) |
| Injection | 3 (25.0) | 9 (33.3) | 0 (0) | 12 (28.6) |
| Oral and injection | 0 (0) | 1 (3.7) | 0 (0) | 1 (2.4) |
| Otherd | 3 (18.8) | 12 (34.3) | 3 (50.0) | 18 (31.6) |
| bDMARDs, n (%) | 18 (72.0) | 25 (50.0) | 5 (50.0) | 48 (56.5) |
| Adalimumab | 6 (33.3) | 9 (36.0) | 2 (40.0) | 17 (35.4) |
| Etanercept | 6 (33.3) | 8 (32.0) | 1 (20.0) | 15 (31.3) |
| Secukinumab | 4 (22.2) | 1 (4.0) | 1 (20.0) | 6 (12.5) |
| Infliximab | 2 (11.1) | 2 (8.0) | 1 (20.0) | 5 (10.4) |
| Golimumab | 0 (0) | 4 (16.0) | 0 (0) | 4 (8.3) |
| Ustekinumab | 0 (0) | 1 (4.0) | 0 (0) | 1 (2.1) |
| Current administration mode,c,e n (%) | ||||
| Oral f | 14 (56.0) | 34 (68.0) | 5 (50.0) | 53 (62.4) |
| Injectionsg | 17 (68.0) | 32 (64.0) | 5 (50.0) | 54 (63.5) |
| Infusion h | 2 (8.0) | 2 (4.0) | 1 (10.0) | 5 (5.9) |
| Previous experience,i n (%) | ||||
| bDMARD experience | 19 (76.0) | 26 (52.0) | 6 (60.0) | 51 (60.0) |
| MTX experience | 16 (64.0) | 45 (90.0) | 5 (50.0) | 66 (77.6) |
| Any injection experience | 21 (84.0) | 40 (80.0) | 7 (70.0) | 68 (80.0) |
| Any infusion experience | 4 (16.0) | 18 (36.0) | 3 (30.0) | 25 (29.4) |
Notes: aIncludes France, Germany, Italy, Spain, and the UK. bAt screening, patients were asked to specify any current prescription medications for PsA other than pain medication or topical medication for plaque psoriasis. This information was reviewed during the subsequent study interview. cPatients could report >1 response; percentages total >100%. dLeflunomide, sulfasalazine, azathioprine, hydroxychloroquine, and others. ePatients were asked whether current PsA medications were taken orally (tablet or pill), by injection (self-injected at home or at doctor’s office or hospital clinic), or by intravenous infusion. fRegardless of mode, the 53 patients receiving an oral mode of treatment for PsA were taking the following types of PsA treatments: steroids (n = 10); csDMARDs (n = 50); MTX (n = 36); bDMARDs (n = 21). gRegardless of mode, the 54 patients receiving an injection for PsA were taking the following types of PsA treatments: steroids (n = 8); csDMARDs (n = 27); MTX (n = 23); bDMARDs (n = 43). hRegardless of mode, the five patients receiving an infusion for PsA were taking the following types of PsA treatments: steroids (n = 0); csDMARDs (n = 4); MTX (n = 3); bDMARDs (n = 5). iPatients were asked "Have you ever taken a biologic to treat your PsA? Have you ever taken any medicine on a regular basis, for any condition, that required injection? Have you ever taken methotrexate to treat your PsA?"
Abbreviations: bDMARD, biologic DMARD; csDMARD, conventional synthetic DMARD; DMARD, disease-modifying antirheumatic drug; MTX, methotrexate; PsA, psoriatic arthritis; tsDMARD, targeted synthetic DMARD.